CSL chief executive Paul Perreault has flagged a staged expansion by the blood products giant in China, as he unveiled an 11 per cent increase in full year net profit.
The result was been buoyed by strong sales of CSL's core immunoglobulin products, driven by increased demand from the US market. It pushed CSL shares up 6.5 per cent to a 12-month high of $233.65 in early trade on Wednesday, though they had eased to $230.33 by late morning.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
